N-methyl-D-aspartate transmission modulates GABAB-mediated inhibition of rat hippocampal pyramidal neurons in vitro.
Slow inhibition was investigated by stimulating inhibitory neurons at the border of stratum radiatum and lacunosum-moleculare with focal microapplications of glutamate, while recording resultant slow inhibitory postsynaptic potentials in CA1 pyramidal neurons in rat hippocampal slices. The slow inhibitory postsynaptic potentials evoked had an average peak amplitude of -2.2 mV, measured at -60 mV. Their peak conductance was 2.5 nS. These events were characterized as slow GABAB inhibitory postsynaptic potentials because they reversed at -90 mV, and were blocked by CGP 35348 (500 microM). Exposure to magnesium-free solutions augmented glutamate-evoked slow inhibitory postsynaptic potentials. Mean peak amplitude and conductance were -3.1 mV and 4.0 nS. Exposure to the N-methyl-D-aspartate antagonist MK-801 (20 microM) allowed separation of the glutamate-triggered slow inhibitory postsynaptic potential into components induced by non-N-methyl-D-aspartate and N-methyl-D-aspartate receptor activation. The N-methyl-D-aspartate component dominated, even under control conditions, and could account for up to 60% of the control slow inhibitory postsynaptic potential. Thus, the activation and recruitment of GABAB-mediated inhibition depend on both non-N-methyl-D-aspartate and N-methyl-D-aspartate-mediated excitation of inhibitory interneurons. Under physiological conditions slow inhibition may act as an important synaptic filtering mechanism, but when N-methyl-D-aspartate-mediated excitation increases, slow inhibition is further recruited, providing an important means to offset excessive excitation.
Benardo
L S
LS
Department of Neurology, State University of New York Health Science Center at Brooklyn 11203, USA.
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000818:Animals; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D058788:GABA-B Receptor Antagonists; D018698:Glutamic Acid / Q000494:pharmacology; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D007395:Interneurons / Q000187:drug effects / Q000502:physiology; D016202:N-Methylaspartate / Q000502:physiology*; D009943:Organophosphorus Compounds / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D010879:Piperazines / Q000494:pharmacology; D017966:Pyramidal Cells / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018080:Receptors, GABA-B / Q000187:drug effects / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D009435:Synaptic Transmission / Q000502:physiology*
D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D018756:GABA Antagonists; D058788:GABA-B Receptor Antagonists; D009943:Organophosphorus Compounds; D010879:Piperazines; D018080:Receptors, GABA-B; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D016202:N-Methylaspartate; D016291:Dizocilpine Maleate; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; C066430:CGP 35348; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid